About Rubraca (rucaparib)
Rubraca® (rucaparib) tablets are a prescription medicine used in adults for the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone): that has spread to other parts of the body, and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene, and you have been treated with certain medicines for your cancer. Rubraca was approved based on response rate and how long patients’ responses lasted. There are ongoing studies to confirm the clinical benefit of Rubraca. Your healthcare provider will perform a test to make sure Rubraca is right for you. It is not known if Rubraca is safe and effective in children.

How does Rubraca work?
There are two major ways to repair DNA damage in cells. If one method fails, the other method can make up the difference and repair DNA. Rubraca is a PARP inhibitor that interrupts (or prevents) one DNA repair system from working. Cells with mutations in genes like BRCA1 and BRCA2 have a decreased ability to repair DNA damage in the other system. If both ways to repair the DNA in a tumor cell are stopped, DNA damage adds up and that causes the tumor cells to die.

What are the potential side effects of Rubraca?
Common side effects include:
- Weakness/fatigue
- Nausea
- Decreased red blood count
- Changes in liver function tests
- Decreased appetite
- Constipation, rash, decreased platelet count
- Vomiting and diarrhea
- Bone marrow problems (myelodysplastic syndrome and acute myeloid leukemia) have been reported with Rubraca, although no cases have been reported in prostate cancer patients.

If you are interested in Rubraca as an option for your prostate cancer treatment, talk to your health care team.

What else should I know?
For males with a female partner who can become pregnant, birth control should be used during treatment and for three months after receiving the last dose of therapy. Men should not donate sperm during use and for three months after the last dose.

Your health care team will conduct blood tests before and while you are receiving therapy to monitor your blood cell counts.
How long may I be on Rubraca?
In the clinical trial, 44% of men who were studied (27 of 62) had their tumors shrink by a meaningful amount. Patient responses ranged from 1.7 to more than 24 months. More than half of the patients who responded had a confirmed response to treatment of more than six months.

How do I take Rubraca?
Rubraca tablets are taken by mouth twice a day about 12 hours apart. You can take it with or without food.

What questions should I ask my health care team?
If you are interested in Rubraca as a treatment option, talk to your health care team.

• Does my cancer have a BRCA1 or BRCA2 mutation? What test will you use to find out? What does a positive test mean for my family and me?
• Is Rubraca a treatment for my type of prostate cancer?
• Which side effects are associated with Rubraca? How are these side effects managed?
• How will my health care team check and monitor for side effects?
• Are there options to help me pay for this medicine?

Where can I find specific information about this treatment?
Additional information can be found at www.rubraca.com and www.rubracaconnections.com.

BRCA Mutations in Prostate Cancer

• Everyone has BRCA1 and BRCA2 genes. These genes are important in every day functions of your cells. Some men may have damaged or “broken” BRCA genes, called mutations. BRCA mutations occur in two ways.
  - They are inherited from a parent (called germline mutation) and are present in every cell in your body.
  - They are acquired at some point during your life (called somatic mutations). Somatic mutations are only present in your tumor and can’t be passed on your children.

• Tests can determine if you have a germline or somatic BRCA mutation.

• About 12% of men (1 in 8 men) with advanced prostate cancer have a mutation in the BRCA1 or BRCA2 genes.

• If the BRCA mutation is a germline mutation, family members may have an increased risk of developing prostate or other types of cancer, like breast or ovarian cancer.
INDICATION

What is Rubraca used for?
Rubraca® (rucaparib) tablets are a prescription medicine used in adults for the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone): that has spread to other parts of the body, and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene, and you have been treated with certain medicines for your cancer.

Rubraca was approved based on response rate and how long patients’ responses lasted. There are ongoing studies to confirm the clinical benefit of Rubraca. Your healthcare provider will perform a test to make sure Rubraca is right for you.

It is not known if Rubraca is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

What are the side effects of Rubraca?
The most common side effects for men in Rubraca clinical studies were weakness/fatigue, nausea, decreased red blood cell count, changes in liver function tests, decreased appetite, constipation, rash, decreased platelet count, vomiting, and diarrhea.

What other medications might interact with Rubraca?
Rubraca can increase the amounts of other medications you may be taking which can increase the risk of side effects. Tell your healthcare provider about all of your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1-415-409-7220 (US toll) or 1-844-CLVS-ONC (1-844-258-7662; US toll-free).